Palbociclib is approved for use in combination with hormonal therapies for patients.
NaMuscla is Europe's first and only licensed product for this indication, and it will be commercialized in Spain by Lupin's partner Exeltis.
It has received the Establishment Inspection Report (EIR).
The transaction is expected to be completed within 60 days of the agreement's signing date.
All claims against the Company in the litigation have now been dismissed, the company announced on Thursday.
Lupin discontinued selling Quinapril tablets in September 2022.
Strides, in 2019, exited its investments in Australia for AUD 394 million.
Lupin Diagnostics Expands its Footprint in Central India
The company has launched this FDC under the brand name Zita – PioMet.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
